Business Context and Reporting Period
Company: Kiora Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 3, 2023
Reporting Period: Events occurring on February 2 and February 3, 2023.
Context: The Company entered into two material definitive agreements with Lincoln Park Capital Fund, LLC ("Lincoln Park") to secure immediate and future equity financing.
Key Financial Metrics and Transaction Details
Private Placement (Immediate):
- Gross Proceeds: $200,000.00
- Securities Issued: 52,798 shares of Common Stock and warrants to purchase up to 105,596 shares.
- Pricing: Combined purchase price of $3.788 per share and two warrants (Minimum Price per Nasdaq Rule 5635(d)).
- Warrant Exercise Price: $3.538 per share.
- Warrant Terms: Exercisable after six months; five-year term; cashless exercise option available if resale registration is ineffective.
Committed Equity Financing (Future):
- Commitment Amount: Up to $10.0 million.
- Term: 36 months from the Commencement Date.
- Structure: At-the-market facility where the Company directs sales to Lincoln Park.
- Daily Limits: Up to 35,000 shares (Regular Purchase) or up to 50,000 shares if price thresholds are met; maximum $1,000,000 per single purchase.
- Exchange Cap: Issuance limited to 359,114 shares (approx. 19.99% of outstanding shares) unless stockholder approval is obtained or the average sale price exceeds $3.538.
- Beneficial Ownership Limit: Lincoln Park cannot be directed to purchase shares if it would result in beneficial ownership exceeding 9.99%.
Material Changes and Liquidity Impact
This filing does not report historical financial performance (revenue, profit, or cash flow) for a specific period. The material change is the establishment of a liquidity facility.
- Liquidity: Immediate infusion of $200,000 via the private placement.
- Future Capital Access: Secured a committed source of up to $10.0 million to support operations, clinical trials, and working capital.
- Dilution: Potential issuance of up to 359,114 shares under the Purchase Agreement, subject to the Exchange Cap and pricing conditions.
Guidance, Outlook, and Risks
Management Commentary and Use of Proceeds:
- Proceeds from the Purchase Agreement are expected to support operations, including clinical trials, working capital, and general corporate purposes.
- The Company retains sole discretion over the timing and amount of sales under the Purchase Agreement.
Risks and Contingencies:
- Variable Rate Transaction Restriction: The Company is prohibited from entering into "Variable Rate Transactions" for a specified period.
- Liquidated Damages: The Company may owe liquidated damages to Lincoln Park if it fails to satisfy public information requirements under Rule 144(c) or fails to deliver shares free of restrictive legends within the specified timeframe.
- Termination: The Company may terminate the Purchase Agreement at any time with one business day's notice at no cost. Lincoln Park cannot terminate during an event of default, though purchases are suspended until cured.
- Short Sales: Lincoln Park is prohibited from short selling or hedging the Common Stock during the term of the agreement.
Investor Verification Checklist
- Verify the closing of the $200,000 private placement and the issuance of the 52,798 shares and warrants.
- Monitor the filing and effectiveness of the registration statement required to trigger the "Commencement Date" for the $10.0 million facility.
- Track the Company's utilization of the Purchase Agreement to assess dilution impact relative to the 19.99% Exchange Cap.
- Confirm compliance with Rule 144(c) public information requirements to avoid liquidated damages.
- Review future filings for any stockholder approval sought to exceed the Exchange Cap.